106 related articles for article (PubMed ID: 38754052)
1. Second Chance for Cure: Stereotactic Ablative Radiotherapy in Oligometastatic Disease.
Salim N; Tumanova K; Popodko A; Libson E
JCO Glob Oncol; 2024 May; 10():e2300275. PubMed ID: 38754052
[TBL] [Abstract][Full Text] [Related]
2. Treatment Outcomes of Stereotactic Ablative Body Radiotherapy on Extra-cranial Oligometastatic and Oligoprogressive Breast Cancer: Mature Results from a Single Institution Experience.
Armstrong S; Makris A; Belessiotis-Richards K; Abdul-Latif M; Ostler P; Shah N; Miles D; Tsang YM
Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):362-369. PubMed ID: 38575431
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial.
Palma DA; Olson R; Harrow S; Gaede S; Louie AV; Haasbeek C; Mulroy L; Lock M; Rodrigues GB; Yaremko BP; Schellenberg D; Ahmad B; Senthi S; Swaminath A; Kopek N; Liu M; Moore K; Currie S; Schlijper R; Bauman GS; Laba J; Qu XM; Warner A; Senan S
J Clin Oncol; 2020 Sep; 38(25):2830-2838. PubMed ID: 32484754
[TBL] [Abstract][Full Text] [Related]
4. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
6. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up.
Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF
Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
8. Total tumor volume as a predictor of survival in patients with multiple oligometastases treated with stereotactic ablative radiotherapy (SABR).
Franzese C; Vernier V; Franceschini D; Comito T; Navarria P; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Marini B; Galdieri C; Mancosu P; Tomatis S; Scorsetti M
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10495-10503. PubMed ID: 37280407
[TBL] [Abstract][Full Text] [Related]
9. A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
Hasan H; Deek MP; Phillips R; Hobbs RF; Malek R; Radwan N; Kiess AP; Dipasquale S; Huang J; Caldwell T; Leitzel J; Wendler D; Wang H; Thompson E; Powell J; Dudley S; Deville C; Greco SC; Song DY; DeWeese TL; Gorin MA; Rowe SP; Denmeade S; Markowski M; Antonarakis ES; Carducci MA; Eisenberger MA; Pomper MG; Pienta KJ; Paller CJ; Tran PT
BMC Cancer; 2020 Jun; 20(1):492. PubMed ID: 32487038
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S
BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760
[TBL] [Abstract][Full Text] [Related]
11. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy.
Nicosia L; Cuccia F; Mazzola R; Ricchetti F; Figlia V; Giaj-Levra N; Rigo M; Tomasini D; Pasinetti N; Corradini S; Ruggieri R; Alongi F
Strahlenther Onkol; 2020 Sep; 196(9):813-820. PubMed ID: 32399637
[TBL] [Abstract][Full Text] [Related]
12. Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer.
Franzese C; Badalamenti M; Teriaca A; De Virgilio A; Mercante G; Cavina R; Ferrari D; Santoro A; Spriano G; Scorsetti M
J Cancer Res Clin Oncol; 2021 May; 147(5):1307-1313. PubMed ID: 33471186
[TBL] [Abstract][Full Text] [Related]
13. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis.
Hong JC; Ayala-Peacock DN; Lee J; Blackstock AW; Okunieff P; Sung MW; Weichselbaum RR; Kao J; Urbanic JJ; Milano MT; Chmura SJ; Salama JK
PLoS One; 2018; 13(4):e0195149. PubMed ID: 29649281
[TBL] [Abstract][Full Text] [Related]
14. Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease.
He K; Hong DS; Tang C; Sezen D; Cox L; Maleki A; Bertolet G; Nguyen QN; Comeaux NI; Schuda L; Chen D; Welsh JW
Radiother Oncol; 2023 Jun; 183():109618. PubMed ID: 36921766
[TBL] [Abstract][Full Text] [Related]
15. Long-term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer.
Wijetunga NA; Dos Anjos CH; Zhi WI; Robson M; Tsai CJ; Yamada Y; Dover L; Gillespie EF; Xu AJ; Yang JT
Cancer Med; 2021 Aug; 10(15):5163-5174. PubMed ID: 34159748
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial.
Olson R; Mathews L; Liu M; Schellenberg D; Mou B; Berrang T; Harrow S; Correa RJM; Bhat V; Pai H; Mohamed I; Miller S; Schneiders F; Laba J; Wilke D; Senthi S; Louie AV; Swaminath A; Chalmers A; Gaede S; Warner A; de Gruijl TD; Allan A; Palma DA
BMC Cancer; 2020 May; 20(1):380. PubMed ID: 32370765
[TBL] [Abstract][Full Text] [Related]
17. Treatment outcomes of stereotactic ablative body radiotherapy on oligometastases from colorectal cancer: early results of a single institution service evaluation.
Duong J; Stewart-Lord A; Nariyangadu P; Harrison M; Tsang YM
BJR Open; 2022; 4(1):20210071. PubMed ID: 36105422
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients.
Ma MW; Li HZ; Gao XS; Liu MZ; Yin H; Yang KW; Chen JY; Ren XY; Wang D
Curr Oncol; 2022 Oct; 29(10):7832-7841. PubMed ID: 36290896
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach.
Comito T; Cozzi L; Clerici E; Campisi MC; Liardo RL; Navarria P; Ascolese A; Tozzi A; Iftode C; De Rose F; Villa E; Personeni N; Rimassa L; Santoro A; Fogliata A; Mancosu P; Tomatis S; Scorsetti M
BMC Cancer; 2014 Aug; 14():619. PubMed ID: 25163798
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionated image-guided breath-hold SABR (stereotactic ablative body radiotherapy) of liver metastases--clinical results.
Boda-Heggemann J; Dinter D; Weiss C; Frauenfeld A; Siebenlist K; Attenberger U; Ottstadt M; Schneider F; Hofheinz RD; Wenz F; Lohr F
Radiat Oncol; 2012 Jun; 7():92. PubMed ID: 22710033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]